title: Safety and feasibility of transcatheter aortic valve implantation in patients with severe persistent thrombocytopenia.
abstract: Untreated symptomatic high-grade aortic stenosis remains a lethal disease. Therefore, a comprehensive evaluation is necessary to obtain the best individual treatment for each patient. Recently, transcatheter aortic valve implantation (TAVI) was developed as an innovative therapy for high-risk and inoperable patients. Persistent thrombocytopenia is an established risk for conventional open heart surgery, but is not covered by traditional surgical risk scores. The aim of the study was the investigation of safety and feasibility of TAVI in patients with severe thrombocytopenia. Because of the complicated outcome of patients with persistent thrombocytopenia undergoing heart surgery, we considered all patients with high-grade aortic stenosis and a thrombocyte count of less than 100 per nl as surgical high-risk patients. Out of these high-risk surgical patients, six patients with symptomatic high-grade aortic stenosis and severe thrombocytopenia were deemed to be TAVI candidates and underwent TAVI procedures in 2010 and 2011 (transfemoral: n = 4; transapical: n = 2) at the University Hospital of Frankfurt. The outcome of these patients was analyzed prospectively in order to document safety and feasibility of TAVI in such patients. All TAVI procedures were performed successfully with excellent functional results. There was no occurrence of major or minor bleeding complications, acute renal failure or nosocomial infection. One patient died of an ischemic stroke 12 days after the procedure. The five remaining patients were alive at the 12-month follow-up without relevant cardiovascular events and excellent valve performance. TAVI is an effective and well tolerated method to treat patients with chronic persistent thrombocytopenia and symptomatic high-grade aortic stenosis, and therefore a reasonable alternative to conventional heart surgery in such patients. The indication for TAVI in patients with thrombocytopenia and symptomatic high-grade aortic stenosis might be generated independently from conventional scoring systems.
authors.affiliation: aDepartment of Cardiology bDepartment of Heart Surgery, Johann Wolfgang Goethe-University Frankfurt, Frankfurt, Germany.
authors.forename: Henrik
authors.initials: H
authors.lastname: Fox
authors.forename: Katrin
authors.initials: K
authors.lastname: Hemmann
authors.forename: Mirko
authors.initials: M
authors.lastname: Doss
authors.forename: Andres
authors.initials: A
authors.lastname: Beiras-Fernandez
authors.forename: Andreas M
authors.initials: AM
authors.lastname: Zeiher
authors.forename: Anton
authors.initials: A
authors.lastname: Moritz
authors.forename: Stephan
authors.initials: S
authors.lastname: Fichtlscherer
authors.forename: Ralf
authors.initials: R
authors.lastname: Lehmann
mesh_terms: D000368:Aged; D001021:Aortic Valve / Q000601:surgery; D005260:Female; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013921:Thrombocytopenia / Q000601:surgery*; D016896:Treatment Outcome